These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 33109196

  • 21. Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness.
    Molina-Crespo Á, Cadete A, Sarrio D, Gámez-Chiachio M, Martinez L, Chao K, Olivera A, Gonella A, Díaz E, Palacios J, Dhal PK, Besev M, Rodríguez-Serrano M, García Bermejo ML, Triviño JC, Cano A, García-Fuentes M, Herzberg O, Torres D, Alonso MJ, Moreno-Bueno G.
    Clin Cancer Res; 2019 Aug 01; 25(15):4846-4858. PubMed ID: 31064780
    [Abstract] [Full Text] [Related]

  • 22. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
    Suzawa K, Toyooka S, Sakaguchi M, Morita M, Yamamoto H, Tomida S, Ohtsuka T, Watanabe M, Hashida S, Maki Y, Soh J, Asano H, Tsukuda K, Miyoshi S.
    Cancer Sci; 2016 Jan 01; 107(1):45-52. PubMed ID: 26545934
    [Abstract] [Full Text] [Related]

  • 23. Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy.
    Ding L, Tian C, Feng S, Fida G, Zhang C, Ma Y, Ai G, Achilefu S, Gu Y.
    Theranostics; 2015 Jan 01; 5(4):378-98. PubMed ID: 25699098
    [Abstract] [Full Text] [Related]

  • 24. Exosomes derived from human umbilical cord mesenchymal stromal cells deliver exogenous miR-145-5p to inhibit pancreatic ductal adenocarcinoma progression.
    Ding Y, Cao F, Sun H, Wang Y, Liu S, Wu Y, Cui Q, Mei W, Li F.
    Cancer Lett; 2019 Feb 01; 442():351-361. PubMed ID: 30419348
    [Abstract] [Full Text] [Related]

  • 25. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA, Vellon L, Lupu R.
    Ann Oncol; 2005 Aug 01; 16(8):1253-67. PubMed ID: 15870086
    [Abstract] [Full Text] [Related]

  • 26. Synthesis and characterization of lipid immuno-nanocapsules for directed drug delivery: selective antitumor activity against HER2 positive breast-cancer cells.
    Sánchez-Moreno P, Ortega-Vinuesa JL, Boulaiz H, Marchal JA, Peula-García JM.
    Biomacromolecules; 2013 Dec 09; 14(12):4248-59. PubMed ID: 24134122
    [Abstract] [Full Text] [Related]

  • 27. The role of HER2 in cancer therapy and targeted drug delivery.
    Tai W, Mahato R, Cheng K.
    J Control Release; 2010 Sep 15; 146(3):264-75. PubMed ID: 20385184
    [Abstract] [Full Text] [Related]

  • 28. Theranostic application of miR-429 in HER2+ breast cancer.
    Cava C, Novello C, Martelli C, Lodico A, Ottobrini L, Piccotti F, Truffi M, Corsi F, Bertoli G, Castiglioni I.
    Theranostics; 2020 Sep 15; 10(1):50-61. PubMed ID: 31903105
    [Abstract] [Full Text] [Related]

  • 29. Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation.
    Barok M, Puhka M, Vereb G, Szollosi J, Isola J, Joensuu H.
    BMC Cancer; 2018 May 02; 18(1):504. PubMed ID: 29720111
    [Abstract] [Full Text] [Related]

  • 30. Engineering blood exosomes for tumor-targeting efficient gene/chemo combination therapy.
    Zhan Q, Yi K, Qi H, Li S, Li X, Wang Q, Wang Y, Liu C, Qiu M, Yuan X, Zhao J, Hou X, Kang C.
    Theranostics; 2020 May 02; 10(17):7889-7905. PubMed ID: 32685027
    [Abstract] [Full Text] [Related]

  • 31. Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy.
    Shi X, Cheng Q, Hou T, Han M, Smbatyan G, Lang JE, Epstein AL, Lenz HJ, Zhang Y.
    Mol Ther; 2020 Feb 05; 28(2):536-547. PubMed ID: 31843452
    [Abstract] [Full Text] [Related]

  • 32. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
    Ferreira RB, Wang M, Law ME, Davis BJ, Bartley AN, Higgins PJ, Kilberg MS, Santostefano KE, Terada N, Heldermon CD, Castellano RK, Law BK.
    Oncotarget; 2017 Apr 25; 8(17):28971-28989. PubMed ID: 28423644
    [Abstract] [Full Text] [Related]

  • 33. Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer.
    Cheng YA, Chen IJ, Su YC, Cheng KW, Lu YC, Lin WW, Hsieh YC, Kao CH, Chen FM, Roffler SR, Cheng TL.
    Biomater Sci; 2019 Aug 01; 7(8):3404-3417. PubMed ID: 31251311
    [Abstract] [Full Text] [Related]

  • 34. Exosomal miR-16-5p as a target for malignant mesothelioma.
    Munson PB, Hall EM, Farina NH, Pass HI, Shukla A.
    Sci Rep; 2019 Aug 12; 9(1):11688. PubMed ID: 31406207
    [Abstract] [Full Text] [Related]

  • 35. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.
    Lou G, Song X, Yang F, Wu S, Wang J, Chen Z, Liu Y.
    J Hematol Oncol; 2015 Oct 29; 8():122. PubMed ID: 26514126
    [Abstract] [Full Text] [Related]

  • 36. Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies.
    Lin YL, Tsai NM, Chen CH, Liu YK, Lee CJ, Chan YL, Wang YS, Chang YC, Lin CH, Huang TH, Wang CC, Chi KH, Liao KW.
    J Nanobiotechnology; 2019 Feb 06; 17(1):25. PubMed ID: 30728015
    [Abstract] [Full Text] [Related]

  • 37. 99mTc-radiolabeled HER2 targeted exosome for tumor imaging.
    Molavipordanjani S, Khodashenas S, Abedi SM, Moghadam MF, Mardanshahi A, Hosseinimehr SJ.
    Eur J Pharm Sci; 2020 May 30; 148():105312. PubMed ID: 32198014
    [Abstract] [Full Text] [Related]

  • 38. Targeted delivery of doxorubicin to HER2 positive tumor models.
    Gomari H, Forouzandeh Moghadam M, Soleimani M, Ghavami M, Khodashenas S.
    Int J Nanomedicine; 2019 May 30; 14():5679-5690. PubMed ID: 31413568
    [Abstract] [Full Text] [Related]

  • 39. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
    Okarvi SM, AlJammaz I.
    Molecules; 2019 Aug 29; 24(17):. PubMed ID: 31470531
    [Abstract] [Full Text] [Related]

  • 40. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I, Tuxen MK, Nielsen DL.
    Cancer Treat Rev; 2014 Mar 29; 40(2):259-70. PubMed ID: 24080156
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.